JAKARTA - PT Indofarma Tbk (INAF) suffered a loss of Rp 24.36 billion in the first half of 2019. This is in contradiction to Indofarma’s performance in the same period last year with a net profit of Rp 253.12 million.
Based on the financial statements in the first semester, this loss was caused by Indofarma's sales which were depressed 12.04% on an annual basis to Rp 368.81 billion. In this period, the majority of the company's sales of 54.50% came from prescription drugs. However, sales of prescription drugs fell by 29.31% to Rp 200.97 billion and sales of medical equipment products rose 185.50% to Rp 23.04 billion.
"INAF remains optimistic that it will reach its 2019 performance target. INAF's business cycle usually increase in the third and fourth quarters in line with tenders at central institutions," Indofarma President Director Arief Pramuhanto said as quoted by Bisnis.com.
Arief is optimistic that sales will increase in the third quarter and fourth quarter in line with tenders at the Ministry of Health. The company will also implement a number of strategies such as adding distributors and subdistributors and focusing on selling products that have positive sales and profit contributions. (LM)